SCHEMBL6178053

SCHEMBL6178053

CCc1nc(-c2ccc(C)cc2)cn1-c1ccc(CCO)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AGER Q15109 4/20 0.43
PTGS1 P23219 1/20 0.43
SMN1; SMN2 Q16637 4/20 0.41
MAPT P10636 3/20 0.41
NPC1 O15118 3/20 0.40
RAB9A P51151 3/20 0.40
ATM Q13315 1/20 0.40
LMNA P02545 1/20 0.38
PDE2A O00408 1/20 0.37
PDE1A P54750 1/20 0.37
PDE1B Q01064 1/20 0.37
PDE3B Q13370 1/20 0.37
PDE1C Q14123 1/20 0.37
PDE3A Q14432 1/20 0.37
SPNS2 Q8IVW8 2/20 0.37
GABRA2 P47869 1/20 0.37
GABRB2 P47870 1/20 0.37
KDM4E B2RXH2 2/20 0.36
ALDH1A1 P00352 2/20 0.36
MEN1 O00255 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6177260 0.89 AGER (0.43) AGERPTGS1SMN1; SMN2MAPTNPC1
SCHEMBL6179004 0.88 AGER (0.42) AGERPTGS1SMN1; SMN2MAPTNPC1
SCHEMBL6175998 0.84 PTGS1 (0.42) AGERPTGS1SMN1; SMN2MAPTNPC1
SCHEMBL6173846 0.78 AGER (0.54) AGERSMN1; SMN2MAPTSPNS2TLR8
SCHEMBL6175631 0.76 PTGS1 (0.55) PTGS1SMN1; SMN2MAPTNPC1RAB9A
SCHEMBL6175993 0.75 PTGS2 (0.41) AGERPTGS1SMN1; SMN2MAPTNPC1
SCHEMBL6177327 0.75 SPNS2 (0.43) AGERSMN1; SMN2MAPTNPC1RAB9A
SCHEMBL6173167 0.75 LMNA (0.39) AGERSMN1; SMN2MAPTNPC1RAB9A
SCHEMBL6176352 0.75 ALDH1A1 (0.44) SMN1; SMN2MAPTNPC1RAB9ALMNA
SCHEMBL6178920 0.75 GPR119 (0.41) PTGS1SMN1; SMN2MAPTNPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6956050-B2 Imidazole compounds as anti-inflammatory and analgesic agents PFIZER, INC. (US) 2005-10-18 US disclosed
EP-1494667-A1 IMIDAZOLE COMPOUNDS AS ANTI-INFLAMMATORY AND ANALGESIC AGENTS Pfizer Japan Inc. (JP) 2005-01-12 EP disclosed
US-20030220372-A1 Imidazole compounds as anti-inflammatory and analgesic agents HIRANO MISATO (JP) 2003-11-27 US disclosed
WO-2003086390-A1 IMIDAZOLE COMPOUNDS AS ANTI-INFLAMMATORY AND ANALGESIC AGENTS PFIZER JAPAN INC. (JP) 2003-10-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030220372-A1 Imidazole compounds as anti-inflammatory and analgesic agents PTGS1, PTGS2, PTGES AGER 4034/4885PTGS1 1/4885SMN1; SMN2 4565/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.